Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female aged 18-65 years old~* Functional Bowel Disorder Severity Index Score above 37~* Normal complete blood count, liver function studies and renal function studies~* Serologies done to rule out Celiac Spure or patient has prior negative EGD with small bowel biopsies which have been negative~* Infectious diarrhea ruled out by stool studies~* Negative colonoscopy~Exclusion Criteria:~* Any history of chronic liver disease, heart disease, pulmonary or renal disease~* Abnormal EKG~* Women with positive pregnancy tests~* Patient on steroids, antacids, or warfarin or chronic pain conditions other than fibromyalgia~* Patients who drink over 2oz alcohol/day on a regular basis Any other causes for diarrhea such as IBD, microscopic colitis, celiac disease, history of abdominal obstruction, pancreatitis, ileus, or any gastrointestinal bleeding.~* Patients with active malignancy in the past five years~* Patient with any history of hypersensitivity reactions to salicylate containing medications due to cross-sensitivity with mesalamine or allergy to mesalamine medications in the past~* Any subjects with fibromyalgia will be excluded from the pain testing portion only~* History of Phenylketonuria due to the aspartame contained in Apriso

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Mesalamine (Type: ACTIVE_COMPARATOR): This group received the drug Mesalamine for 12 weeks then a wash out for 3 weeks prior to crossing over to the placebo arm.
- Placebo (Type: PLACEBO_COMPARATOR): This group will receive the Placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).